Juno Therapeutics Inc.'s origins in three of the country's top oncology centers apparently has done plenty to help financing options for the Seattle-based firm, which added $134 million in series B cash to boost its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline. In less than 12 months, the Seattle-based company has raised more than $300 million. Read More
Regeneron Pharmaceuticals Inc. had more good news to crow about Tuesday, reporting that second quarter global net sales of Eylea (aflibercept) increased 53 percent, to $662 million, over the same period a year earlier, including sales of $415 million in the U.S. – a 26 percent jump based on a modest decrease in distributor inventory in the second quarter of 2013 – and $247 million in the rest of world. Read More
Walvax Biotechnology Co. Ltd. (SZ:300142) raised an additional ¥450 million (US$73 million) through a private placement. The private placement of 15 million shares will be offered to Li Yunchun, one of Walvax's major shareholders, as well as investment companies Yuxi Gaoxin Private Capital Management, Shenzhen Deruntianqing Investment Management Partnership and Yuxi Runtai Investment Management Partnership. Read More
SHANGHAI – For Xueming Qian, CEO and founder of Mabspace Co. Ltd., an antibody discovery engine based in Suzhou, the writing was on the wall. While pharma was de-emphasizing early stage research and putting it into the hands of biotechs in the U.S., the economy in China had hit an inflection point, the momentum was building. China was the place to be. Read More
Diurnal Ltd. is raising up to £6 million (US$10.1 million) to complete phase III development of Chronocort, a modified-release formulation of hydrocortisone, for treating congenital adrenal hyperplasia (CAH). Read More
BOGOTA, Colombia – During the Cold War, Soviet researchers studied the medical applications of bacteriophages, viruses that attack bacteria, but remained isolated from advances in antibiotics on the other side of the Iron Curtain. Read More
Genoa Pharmaceuticals Inc., of San Diego, said the FDA has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program, inhaled GP-101 for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
Heritage Pharmaceuticals Inc., of Eatontown, N.J., signed an exclusive development, supply and distribution agreement with Dexcel Pharma Ltd., of Or Akiva, Israel, for an undisclosed extended-release abbreviated new drug application product that generates annual U.S. sales of approximately $60 million. Read More
Integra Lifesciences Holdings Corp., of Plainsboro, N.J., completed a multicenter trial evaluating the safety and effectiveness of Integra Dermal Regeneration Template, its bilayer skin replacement system designed to help close wounds and regenerate skin cells for the treatment of diabetic foot ulcers. Read More
